Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 8/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | HTRA1 | Q92743 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723426 | 0.86 | NPSR1 (0.41) | ALDH1A1 | |
| SCHEMBL20556229 | 0.86 | NPSR1 (0.41) | ALDH1A1 | |
| SCHEMBL20556230 | 0.86 | NPSR1 (0.41) | ALDH1A1 | |
| SCHEMBL26508048 | 0.86 | NPSR1 (0.41) | ALDH1A1 | |
| SCHEMBL806769 | 0.85 | TAS1R3 (0.50) | MMP1MMP3ALDH1A1MMP9 | |
| SCHEMBL23447539 | 0.82 | LCK (0.39) | RENTSHRALDH1A1THRBCYP2C9 | |
| SCHEMBL23574378 | 0.82 | SMN1; SMN2 (0.43) | ALDH1A1 | |
| SCHEMBL16463916 | 0.82 | KLK5 (0.53) | MMP1RENTSHRMMP3ALDH1A1 | |
| SCHEMBL23574381 | 0.82 | SMN1; SMN2 (0.43) | ALDH1A1 | |
| SCHEMBL16463914 | 0.82 | KLK5 (0.53) | MMP1RENTSHRMMP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072635-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200239519-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239519-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | MMP1 330/4885REN 861/4885HTRA1 200/4885 |
| US-11072635-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | MMP1 330/4885REN 861/4885HTRA1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.